Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Novartis Pharma Services AG
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Safety and tolerability of ACZ885 (Canakinumab) in patients with gout
The purpose of this third extension study is to provide additional long-term safety and tolerability data of canakinumab over an 18-month time period on patients who have completed the extension studi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral RSV604 in healthy adults experimentally infected with respiratory syncytial virus
- To evaluate the antiviral activity of RSV604, given orally, on nasal RSV load, as measured by RT-PCR, in healthy adults experimentally inoculated with a challenge virus of RSV. - To evaluate the s...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC)
To compare overall survival between the ASA404 plus docetaxel group and the placebo plus docetaxel group
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis assessing different doses and dose regimens
Efficacy of secukinumab over 52 weeks based on PASI, in two different doses and two treatment regimens (fixed interval vs personalized treatment), in subjects with moderate to severe chronic plaque-ty...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to severe hypertension
The primary objective of the study is to demonstrate that a once daily dosing regimen of the triple combination of aliskiren/amlodipine/HCTZ is superior to the double combinations of aliskiren/amlodip...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, double-blind, double-dummy, active controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares, for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective
The two co-primary objectives of this study are: • To confirm that canakinumab 150 mg s.c. is superior to triamcinolone acetonide 40 mg i.m. with respect to patient’s assessment of gout pain intensity...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
To determine the objective response rate (ORR) (including complete response and partial response) of RAD001 10 mg po qd monotherapy in patients with advanced (unresectable or metastatic) pancreatic NE...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A study of everolimus plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced neuroendocrine cancer of gastrointestinal or lung origin. Klinické hodnocení everolimu plus nejlepší podpůrná léčba versus placebo plus nejlepší podpůrná léčba v léčbě pacientů s pokročilými neuroendokrinními nádory gastrointestinálního nebo plicního původu
Determinate whether treatment with everolimus plus best supportive care prolongs PFS compared to placebo plus best supportive care in patients with advanced NET of GI or lung origin
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
An interventional study of PDR001 in adult patients with nasopharyngeal carcinoma (NPC) who have progressed on standard treatment
To assess the efficacy of PDR001 versus investigator’s choice of chemotherapy in patients with moderately differentiated / undifferentiated locally advanced recurrent or metastatic NPC who progressed...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation
• To facilitate the management of patients on maintenance immunosuppression therapy who are completing everolimus trials, • To provide everolimus maintenance therapy through this access program and ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant